Mirum Pharmaceuticals, Inc.
NASDAQ:MIRMBiotechnology
+$3.89 today
- Market cap
- $6.04B
- Beta
- 0.51
- P/E (TTM)
- -7.8
- EPS (TTM)
- -$13.57
Volume 0.50M
Average 0.95M
MIRM EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Mirum Pharmaceuticals, Inc.NASDAQ: MIRM
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA turns negative
Q2 FY2026 EBITDA was -$11.37M, compared with $4.19M a year earlier. Trailing-twelve-month EBITDA was -$776.79M.
Context
- EBITDA amounted to 3.3% of revenue in FY2025, down 11.2 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 9 analysts of -$688.74M (-4102.9%) for the fiscal year ending Dec 2026, a slowdown from the +135.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$11.37M+98.5% QoQ
- Last fiscal yearDec 2025
- $17.21M+135.1% YoY
- LTMJun 2026
- -$776.79M-4033.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -371.5% | -361.1% | +10.4 pp |
| 1 year | +135.1% | -4102.9% | -4238.1 pp |
| 3-year CAGR | — | +169.6% | — |
| 5-year CAGR | +118.5% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 17.21M USD
- Year-over-year change
- +135.1%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.21M | +135.1% |
| FY2024 | 2024-12-31 | (48.97M) | +64.1% |
| FY2023 | 2023-12-31 | (136.49M) | -11.1% |
| FY2022 | 2022-12-31 | (122.85M) | -87.9% |
| FY2021 | 2021-12-31 | (65.39M) | — |
EBITDA vs competitors
How MIRM compares with its peers on the latest reported figures
- MIRM's LTM Jun 2026 EBITDA of -$776.79M is the lowest of the 8 companies compared; the peer median is -$106.58M.
- Its year-over-year change of -4033.6% is the lowest of 8, against a peer median of -9.5%.
- EBITDA amounts to 125.7% of revenue for MIRM, versus a peer median of 75.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$46.56M | +46.6% | — | 67.3% | |
| LTM Mar 2026 | -$67.53M | -3.7% | — | 148.9% | |
| LTM Mar 2026 | -$88.27M | +2.7% | — | 245200.0% | |
| LTM Sep 2026 | -$106.58M | -372.0% | — | 16.4% | |
| LTM Jun 2026 | -$292.07M | -9.5% | — | 22.7% | |
| LTM Mar 2026 | -$418.36M | -158.4% | — | 633.4% | |
| LTM Mar 2026 | -$503.35M | -11.9% | — | 75.2% | |
| LTM Jun 2026 | -$776.79M | -4033.6% | — | 125.7% | |
| Peer median (excluding MIRM) | -$106.58M | -9.5% | — | 75.2% | |
Competitors are the stored peer set for MIRM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 19.14M | 77.06M | 186.37M | 336.89M | 521.31M |
| Cost of Revenue | 1.9M | 12.37M | 47.04M | 81.64M | 100.58M |
| Gross Profit | 17.24M | 64.69M | 139.34M | 255.25M | 420.73M |
| Gross Margin | 90.1% | 83.9% | 74.8% | 75.8% | 80.7% |
| Research & Development | 131.43M | 106.84M | 102.61M | 140.63M | 186.18M |
| Selling, General & Admin | 59.22M | 89.07M | 145.88M | 202.22M | 257.03M |
| Operating Expenses | 190.65M | 195.91M | 248.49M | 342.85M | 443.21M |
| Depreciation & Amortization | 975K | 3.24M | 10.83M | 23.63M | 24.24M |
| EBITDA | (65.39M) | (122.85M) | (136.49M) | (48.97M) | 17.21M |
| EBITDA Margin | -341.7% | -159.4% | -73.2% | -14.5% | 3.3% |
| Operating Income | (173.41M) | (131.22M) | (109.15M) | (87.61M) | (22.14M) |
| Operating Margin | -906.1% | -170.3% | -58.6% | -26.0% | -4.2% |
| Interest Income | 366K | 3.86M | 13.74M | 13.79M | 12.73M |
| Interest Expense | 17.59M | 15.98M | 15.11M | 14.31M | 14.39M |
| Other Income / Expenses | 89.46M | (10.85M) | (53.27M) | 694K | 709K |
| Income Before Tax | (83.95M) | (142.07M) | (162.42M) | (86.91M) | (21.43M) |
| Pre-Tax Margin | -438.7% | -184.4% | -87.1% | -25.8% | -4.1% |
| Income Tax Expense | 37K | (6.41M) | 991K | 1.03M | 1.94M |
| Net Income | (83.99M) | (135.67M) | (163.42M) | (87.94M) | (23.36M) |
| Net Margin | -438.9% | -176.0% | -87.7% | -26.1% | -4.5% |
| EPS (Basic) | (2.77) | (4.01) | (4.00) | (1.85) | (0.47) |
| EPS (Diluted) | (2.77) | (4.02) | (4.00) | (1.85) | (0.47) |
| Weighted Avg Shares | 30.32M | 33.84M | 40.89M | 47.52M | 50.2M |
| Weighted Avg Shares (Diluted) | 30.32M | 33.98M | 40.89M | 47.52M | 50.2M |
Mirum Pharmaceuticals, Inc.
NASDAQ:MIRM
Intrinsic Alpha fair value
Locked
Current Price
$92.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.